Acasti Pharma Inc. – NASDAQ:ACST

Add to watchlist

Market closed

Open in about 15 hours

-1.89%

month

-8.23%

quarter

+447.37%

year

Market Cap	34.17M
Enterprise value	N/A

P/E	-1.34
EV/Sales	N/A
EV/EBITDA	0.35
Price/Sales	N/A
Price/Book	0.21
PEG ratio	-0.01
EPS	-1.58

Revenue	N/A
EBITDA	-12.01M
Income	-13.29M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Acasti Pharma Inc. (NASDAQ:ACST): Profit margin
Jun 2023	0	-4.02M
Sep 2023	0	-3.71M
Dec 2023	0	-2.39M
Mar 2024	0	-3.16M

Acasti Pharma Financials Estimate

Q Y

Acasti Pharma Inc. (NASDAQ:ACST): Analyst Estimates
Sep 2025	0	-3.68M
Oct 2025	0	-3.01M
Dec 2025	0	-3.63M
Mar 2026	0	-4.30M

Analysts Price target
Financials & Ratios estimates

Acasti Pharma Inc. (NASDAQ:ACST): Debt to assets
Jun 2023	73033000	9.02M	12.35%
Sep 2023	78210000	11.46M	14.66%
Dec 2023	76185000	11.50M	15.1%
Mar 2024	73300000	11.55M	15.77%

Acasti Pharma Inc. (NASDAQ:ACST): Cash Flow
Jun 2023	-6.24M	0	0
Sep 2023	-2.11M	110K	7.35M
Dec 2023	-1.89M	-6.55M	-65.33K
Mar 2024	-2.17M	6.49M	61.02K

Acasti Pharma alternative data

Acasti Pharma Inc. (NASDAQ:ACST): Employee count
Aug 2023	32
Sep 2023	32
Oct 2023	32
Nov 2023	32
Dec 2023	32
Jan 2024	32
Feb 2024	32
Mar 2024	32
Apr 2024	32
May 2024	32
Jun 2024	32
Jul 2024	32

Acasti Pharma
Hedge Funds Holdings Q1 2023

0.31% +0.19%

of ACST is owned by hedge funds

6 -2

hedge funds hold ACST stock

136.49K +86.16K

shares is hold by hedge funds

ACST hedge funds holdings changes

Acasti Pharma Inc. (NASDAQ:ACST): Insider trades (number of shares)
Period	Buy	Sel
Aug 2023	381	0
Sep 2023	1099103	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	25 Sep 2023	KAVURU VIMAL director, 10 percent owner: director, 10 percent owner:	Common Shares	676,371	$1.85	$1,249,934
Purchase	25 Sep 2023	KAVURU VIMAL director, 10 percent owner: director, 10 percent owner:	Common Warrants (right to buy)	422,732	$3	$1,269,464
Purchase	31 Aug 2023	OLDS DONALD director director	Common Shares	381	$2.05	$781

Status	Patent	Filling date	Issue date
Application	Application PROCESS OF PRODUCING CONCENTRATED THERAPEUTIC PHOSPHOLIPID COMPOSITION FROM KRILL EXTRACTS CONTAINING HIGH LEVEL OF FREE FATTY ACIDS Filling date: 7 Feb 2020 Issue date: 28 Apr 2022	7 Feb 2020	28 Apr 2022
Application	Application APPARATUS FOR METERING AND DISPENSING VISCOUS SUBSTANCE Filling date: 9 May 2019 Issue date: 5 Aug 2021	9 May 2019	5 Aug 2021
Application	Application PROCESS FOR THE MANUFACTURE OF ENRICHED PHOSPHOLIPID COMPOSITIONS Filling date: 15 May 2019 Issue date: 18 Mar 2021	15 May 2019	18 Mar 2021

Acasti Pharma
Earnings Call Transcripts

Quarter	Transcript
Q3 2023 14 Feb 2023	Q3 2023 Earnings Call Transcript
Q2 2023 14 Nov 2022	Q2 2023 Earnings Call Transcript
Q1 2023 11 Aug 2022	Q1 2023 Earnings Call Transcript
Q4 2022 21 Jun 2022	Q4 2022 Earnings Call Transcript

ACST earnings call transcripts

Acasti Pharma
Executives

Insider	Age	Compensation
Ms. Janelle D'Alvise (1955) Pres, Chief Executive Officer, Corporation Sec. & Director	70	$428,040
Mr. Brian D. Ford CPA, CA (1959) Chief Financial Officer	66	$364,820
Dr. Pierre Lemieux M.D., Ph.D. (1965) Co-Founder, Chief Operating Officer & Chief Scientific Officer	60	$276,380

Acasti Pharma
Latest News

Friday, 25 October 2024
08:00	Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.	globenewswire.com
Wednesday, 25 September 2024
07:30	Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104	globenewswire.com
Thursday, 5 September 2024
10:35	Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference	globenewswire.com
Friday, 9 August 2024
08:00	Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update	globenewswire.com
Wednesday, 10 July 2024
10:41	Is Acasti Pharma (ACST) Outperforming Other Medical Stocks This Year?	zacks.com
Thursday, 27 June 2024
16:05	Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial	globenewswire.com
Friday, 21 June 2024
08:00	Acasti Announces Year-End 2024 Financial Results, Provides Business Update	globenewswire.com
Tuesday, 18 June 2024
12:31	Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024	investorplace.com
Tuesday, 28 May 2024
16:05	Acasti Pharma to Attend BIO International Convention 2024	globenewswire.com
Thursday, 23 May 2024
06:45	The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom	investorplace.com
Monday, 12 February 2024
08:00	Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights	globenewswire.com
Wednesday, 13 December 2023
08:00	Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024	GlobeNewsWire
Wednesday, 6 September 2023
08:00	Acasti to Participate in the H.C. Wainwright Global Investment Conference	GlobeNewsWire
Wednesday, 9 August 2023
16:05	Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting	GlobeNewsWire
Tuesday, 28 February 2023
11:18	Has Acasti Pharma (ACST) Outpaced Other Medical Stocks This Year?	Zacks Investment Research
Tuesday, 14 February 2023
15:53	Acasti Pharma Inc. (ACST) Q3 2023 Earnings Call Transcript	Seeking Alpha
Tuesday, 24 January 2023
16:15	Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31	GlobeNewsWire
Friday, 13 January 2023
09:00	Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18	GlobeNewsWire
Thursday, 5 January 2023
09:00	Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures	GlobeNewsWire
Wednesday, 28 December 2022
13:16	Best Penny Stocks To Buy Now? 4 Stocks Under $4 To Watch	PennyStocks
Monday, 14 November 2022
23:23	Acasti Pharma Inc. (ACST) Q2 2023 Earnings Call Transcript	Seeking Alpha
Wednesday, 9 November 2022
16:15	Acasti Pharma to Present at Q4 Investor Summit	GlobeNewsWire
Monday, 7 November 2022
16:15	Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022	GlobeNewsWire
Wednesday, 14 September 2022
16:15	Acasti Pharma to Participate in the Lytham Partners Fall 2022 Investor Conference	GlobeNewsWire
Monday, 12 September 2022
09:00	Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment Conference	GlobeNewsWire
Tuesday, 2 August 2022
16:15	Acasti Pharma to Report First Quarter 2023 Financial Results on Thursday, August 11, 2022	GlobeNewsWire
Thursday, 16 June 2022
16:15	Acasti Pharma Schedules Fiscal Year 2022 Business Update Conference Call	GlobeNewsWire
Wednesday, 18 May 2022
11:28	Acasti Pharma's IV Hemorrhage Drug Candidate At Par With Oral Nimodipine	Benzinga
09:48	Penny Stocks To Buy Now? 6 To Watch Under $1 This Week	PennyStocks
Monday, 25 April 2022
08:30	Acasti Pharma to Present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on April 28th	GlobeNewsWire

Frequently Asked Questions (FAQ)

When is Acasti Pharma's next earnings date?

Unfortunately, Acasti Pharma's (ACST) next earnings date is currently unknown.
Does Acasti Pharma pay dividends?

No, Acasti Pharma does not pay dividends.
How much money does Acasti Pharma make?

Acasti Pharma has a market capitalization of 34.17M.
What is Acasti Pharma's stock symbol?

Acasti Pharma Inc. is traded on the NASDAQ under the ticker symbol "ACST".
What is Acasti Pharma's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Acasti Pharma?

Shares of Acasti Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Acasti Pharma's key executives?
Acasti Pharma's management team includes the following people:
- Ms. Janelle D'Alvise Pres, Chief Executive Officer, Corporation Sec. & Director(age: 70, pay: $428,040)
- Mr. Brian D. Ford CPA, CA Chief Financial Officer(age: 66, pay: $364,820)
- Dr. Pierre Lemieux M.D., Ph.D. Co-Founder, Chief Operating Officer & Chief Scientific Officer(age: 60, pay: $276,380)
Is Acasti Pharma founder-led company?

Yes, Acasti Pharma is a company led by its founder Dr. Pierre Lemieux M.D., Ph.D..
How many employees does Acasti Pharma have?

As Jul 2024, Acasti Pharma employs 32 workers.
When Acasti Pharma went public?

Acasti Pharma Inc. is publicly traded company for more then 13 years since IPO on 7 Feb 2012.
What is Acasti Pharma's official website?

The official website for Acasti Pharma is acastipharma.com.
Where are Acasti Pharma's headquarters?

Acasti Pharma is headquartered at 3009 boulevard de la Concorde East, Laval, QC.
How can i contact Acasti Pharma?

Acasti Pharma's mailing address is 3009 boulevard de la Concorde East, Laval, QC and company can be reached via phone at +45 06872262.

Acasti Pharma Inc.

acastipharma.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.

+45 06872262

3009 boulevard de la Concorde East
Laval, QC H7E 2B5

CIK: 0001444192
ISIN: CA00430K8656
CUSIP: 00430K402